ORGS Orgenesis Inc.

Orgenesis Inc is engaged in developing clinical stage technology that with the capacity to induce a shift in developmental fate of cells from liver & converting them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes.

$2.42  -0.10 (-3.97%)
As of 06/30/2022 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/01/2013
Outstanding shares:  24,820,756
Average volume:  25,979
Market cap:   $62,548,305
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -3.37
PB ratio:   1.53
PS ratio:   0.00
Return on equity:   34.31%
Net income %:   40.16%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy